Ⅳ期NSCLC原发肿瘤三维放射治疗失败模式分析

doi:10.3760/cma.j.cn113030-20211207-00502

摘要
图/表
参考文献(24)
相关文章 (15)
点击分布统计
下载分布统计

全文: PDF (0 KB) HTML (1 KB)
输出: BibTeX | EndNote (RIS) 背景资料

摘要目的探讨Ⅳ期NSCLC原发肿瘤三维放疗联合药物一线治疗的失败模式特点及放疗相关因素的影响。方法选择2003年3月至2020年7月708例初诊Ⅳ期NSCLC患者,χ²检验失败模式单因素分析;Kaplan‐Meier法并log‐rank检验、Cox回归模型多因素生存分析。结果 708例首次失败发生率71.2%,≤6个月、>6~12个月、>12~24个月、>24个月的治疗失败发生率分别为22.7%、28.8%、13.3%、6.4%,中位生存期分别为7.2、13.4、22.2、37.6个月,差异有统计学意义（χ²=226.013,P<0.001）。复发失败发生率为21.3%,寡转移和非寡转移的复发失败发生率差异无统计学意义。转移失败发生率为66.3%,从高到低依次为脑>骨>肺>胸膜腔>肝>远处淋巴结>肾上腺>其他部位,约1/2病例发生新增转移器官,约1/3病例发生原转移器官进展。转移状态、治疗失败发生时间、病理类型、性别、综合治疗强度是预后的独立影响因素。结论 Ⅳ期NSCLC原发肿瘤放疗的失败模式与一线药物治疗不同,局部失败显著降低,转移失败为主,脑转移发生率最高,治疗失败发生时间越晚,OS期越长。寡转移、女性、非鳞癌、治疗失败发生时间晚、4~6个周期化疗同期放疗剂量≥63 Gy是延长生存的独立预后因子。

	服务

	把本文推荐给朋友
	加入我的书架
	加入引用管理器
	E-mail Alert
	RSS
	作者相关文章
	吴新宇
	苏胜发
	欧阳伟炜
	李青松
	马筑
	杨文刚
	陈霞霞
	耿一超
	卢冰

关键词 ：癌,非小细胞肺,Ⅵ期, 放射疗法, 原发肿瘤, 失败模式, 生存

Abstract：Objective To explore the characteristics of failure patterns of three‐dimensional radiotherapy combined with first‐line drug therapy for primary tumors of stage Ⅳ non‐small cell lung cancer(NSCLC)and investigate the influence of radiotherapy‐related factors. Methods 708 patients newly‐diagnosed with stage Ⅳ NSCLC from March 2003 to July 2020 were selected. Chi‐square test was used for univariate analysis of failure patterns. Kaplan‐Meier method, Log‐rank test and Cox regression model were employed for multivariate analysis. Results The incidence of first‐line treatment failure in 708 cases was 71.2%, and the incidence of treatment failure was 22.7%, 28.8%, 13.3%, and 6.4% for ≤6 months, >6-12 months, >12-24 months, and>24 months, respectively, and the median survival time was 7.2, 13.4, 22.2, and 37.6 months, which was significantly different(χ²=226.013,P<0.001). The incidence of recurrence failure(RF)was 21.3%.There was no significant difference in the incidence of RF between oligometastasis(OM)and non‐oligometastasis(NOM). The incidence of DF was 66.3% and the order of incidence was brain>bone>lung>pleural cavity>liver>distant lymph nodes>adrenal gland>other sites, occurring in approximately 1/2 of AM and 1/3 of PSM cases. Metastatic status, time to treatment failure, pathological type, gender, combined treatment intensity were the independent influencing factors for predicting prognosis. Conclusions The failure pattern of radiotherapy for primary tumors of stage Ⅳ NSCLC is different from that of first‐line drug therapy, with significantly lower local failure and predominantly metastatic failure. The incidence of brain metastasis is the highest. The later time to treatment failure, the longer the overall survival(OS). OM, female, non‐squamous cell carcinoma, late treatment failure, 4-6 cycles of chemotherapy over the same period ≥63 Gy are the independent prognostic factors for prolonging survival.

Key words： Carcinoma,non‐small cell lung,stage Ⅵ Radiation therapy Primary tumor Pattern of failure Survival

收稿日期: 2021-12-07

基金资助:贵州省科技计划支撑项目[黔科合支撑（2019）2795]

通讯作者: 卢冰,Email：lbgymaaa@163.com

引用本文:

吴新宇,苏胜发,欧阳伟炜等. Ⅳ期NSCLC原发肿瘤三维放射治疗失败模式分析[J]. 中华放射肿瘤学杂志, 2022, 31(8): 691-697.

Wu Xinyu,Su Shengfa,Ouyang Weiwei et al. The patterns of failure with three‐dimensional radiation therapy for primary tumors of stage Ⅳ NSCLC[J]. Chinese Journal of Radiation Oncology, 2022, 31(8): 691-697.

链接本文:

http://journal12.magtechjournal.com/Jweb_fszlx/CN/10.3760/cma.j.cn113030-20211207-00502 或 http://journal12.magtechjournal.com/Jweb_fszlx/CN/Y2022/V31/I8/691

[1] Chen VW, Ruiz BA, Hsieh MC, et al.Analysis of stage and clinical/prognostic factors for lung cancer from SEER registries: AJCC staging and collaborative stage data collection system[J]. Cancer,2014,120(Suppl23):3781‐3792.DOI:10.1002/cncr.29045.
[2] Arbour KC, Riely GJ.Systemic Therapy for Locally Advanced and Metastatic Non‐Small Cell Lung Cancer: A Review[J]. JAMA, 2019,322(8): 764‐774.DOI: 10.1001/jama.2019.11058.
[3] Schwer AL, Gaspar LE.Update in the treatment of brain metastases from lung cancer[J]. Clin Lung Cancer, 2006,8(3): 180‐186.DOI: 10.3816/CLC.2006.n.045.
[4] Pao W, Miller VA, Politi KA, et al.Acquired resistance of lung adenocarcinomas to gefitinib or erlotinib is associated with a second mutation in the EGFR kinase domain[J]. PLoS Med, 2005,2(3): e73.DOI: 10.1371/journal.pmed.0020073.
[5] Pao W, Wang TY, Riely GJ, et al.KRAS mutations and primary resistance of lung adenocarcinomas to gefitinib or erlotinib[J]. PLoS Med, 2005,2(1):e17.DOI:10.1371/journal.pmed.0020017.
[6] Rusthoven KE, Hammerman SF, Kavanagh BD, et al.Is there a role for consolidative stereotactic body radiation therapy following first‐line systemic therapy for metastatic lung cancer?A patterns‐of‐failure analysis[J]. Acta Oncol, 2009,48(4): 578‐583.DOI: 10.1080/02841860802662722.
[7] Higginson D, Chen R, Tracton G, et al.The impact of local and regional disease extent on overall survival in patients with advanced stage ⅢB/Ⅳ non‐small cell lung carcinoma[J]. Int J Radiat Oncol Biol Phys, 2012,84(3): e385‐392.
[8] 胡小龙,李宏奇,徐向升,等.43例寡转移NSCLC立体定向放疗结果分析[J]. 中华放射肿瘤学杂志,2017,26(10): 1141‐1146.DOI: 10.3760/cma.j.issn.1004‐4221.2017.10.007.
Hu XL, Li HQ, Xu XS, et al.Result of stereotactic radiotherapy of oligometastasis non‐small cell lung cancer[J]. Chin J Radiat Oncol, 2017,26(10): 1141‐1146.DOI: 10.3760/cma.j.issn.1004‐4221.2017.10.007.
[9] Chen X, Chen H, Poon I, et al.Late metastatic presentation is associated with improved survival and delayed wide‐spread progression after ablative stereotactic body radiotherapy for oligometastasis[J]. Cancer Med, 2021,10(18): 6189‐6198.DOI: 10.1002/cam4.4133.
[10] Su S, Hu Y, Ouyang W, et al.Might radiation therapy in addition to chemotherapy improve overall survival of patients with non‐oligometastatic stage Ⅳ non‐small cell lung cancer?:secondary analysis of two prospective studies[J]. BMC Cancer, 2016,16(1): 908.DOI: 10.1186/s12885‐016‐2952‐3.
[11] Su S, Li T, Lu B, et al.Three‐dimensional radiation therapy to the primary tumor with concurrent chemotherapy in patients with stage Ⅳ non‐small cell lung cancer: results of a multicenter phase 2 study from PPRA‐RTOG, China[J]. Int J Radiat Oncol Biol Phys, 2015,93(4): 769‐777.
[12] Petrelli F, Ghidini A, Cabiddu M, et al.Addition of radiotherapy to the primary tumour in oligometastatic NSCLC: a systematic review and meta‐analysis[J]. Lung Cancer, 2018,126:194‐200.DOI: 10.1016/j.lungcan.2018.11.017.
[13] De Ruysscher D, Wanders R, Hendriks LE, et al.Progression‐free survival and overall survival beyond 5 years of NSCLC patients with synchronous oligometastases treated in a prospective phase II trial(NCT 01282450)[J]. J Thorac Oncol, 2018,13(12): 1958‐1961.DOI: 10.1016/j.jtho.2018.07.098.
[14] Eisenhauer EA, Therasse P, Bogaerts J, et al.New response evaluation criteria in solid tumours: revised RECIST guideline(version 1.1)[J]. Eur J Cancer, 2009,45(2): 228‐247.
[15] Su SF, Hu YX, Ouyang WW, et al.Overall survival and toxicities regarding thoracic three‐dimensional radiotherapy with concurrent chemotherapy for stage Ⅳ non‐small cell lung cancer: results of a prospective single‐center study[J]. BMC Cancer, 2013,13:474.DOI: 10.1186/1471‐2407‐13‐474.
[16] Postmus PE, Brambilla E, Chansky K, et al.The IASLC lung cancer staging project: proposals for revision of the M descriptors in the forthcoming(seventh)edition of the TNM classification of lung cancer[J]. J Thorac Oncol, 2007,2(8): 686‐693.DOI: 10.1097/JTO.0 b013e31811f4703.
[17] 李凤虎,卢冰,付和谊,等.546例Ⅳ期非小细胞肺癌远处转移特点的放疗意义分析[J]. 中华放射肿瘤学杂志,2012,21(2): 122‐125.DOI: 10.3760/cma.j.issn.1004‐4221.2012.02.008.
Li FH, Lu B, Fu HY, et al.Metastasis features of 546 patients with stage Ⅳ non‐small cell lung cancer at first visit and the significance in radiotherapy[J]. Chin J Radiat Oncol,2012,21(2):122‐125.DOI:10.3760/cma.j.issn.1004‐4221.2012.02.008.
[18] Hellman S, Weichselbaum RR.Oligometastases[J]. J Clin Oncol, 1995,13(1): 8‐10.DOI: 10.1200/JCO.1995.13.1.8.
[19] Iyengar P, Wardak Z, Gerber DE, et al.Consolidative radiotherapy for limited metastatic non‐small‐cell lung cancer: a phase 2 randomized clinical Trial[J]. JAMA Oncol, 2018,4(1): e173501.DOI: 10.1001/jamaoncol.2017.3501.
[20] Arrieta O, Maldonado F, Turcott JG, et al.Prophylactic cranial irradiation reduces brain metastases and improves overall survival in high‐risk metastatic non‐small cell lung cancer patients: a randomized phase 2 study(PRoT‐BM trial)[J]. Int J Radiat Oncol Biol Phys, 2021,110(5): 1442‐1450.DOI: 10.1016/j.ijrobp.2021.02.044.
[21] Hörner‐Rieber J, Bernhardt D, Blanck O, et al.Long‐term follow‐up and patterns of recurrence of patients with oligometastatic NSCLC treated with pulmonary SBRT[J]. Clin Lung Cancer, 2019,20(6): e667‐e677.DOI: 10.1016/j.cllc.2019.06.024.
[22] Ma L, Qiu B, Zhang J, et al.Survival and prognostic factors of non‐small cell lung cancer patients with postoperative locoregional recurrence treated with radical radiotherapy[J]. Chin J Cancer,2017,36(1):93.DOI:10.1186/s40880‐017‐0261‐0.
[23] Petrelli F, Ghidini A, Cabiddu M, et al.Addition of radiotherapy to the primary tumour in oligometastatic NSCLC: a systematic review and meta‐analysis[J]. Lung Cancer, 2018,126:194‐200.DOI: 10.1016/j.lungcan.2018.11.017.
[24] 邓蓉,李涛,李建成,等.Ⅳ期NSCLC化疗同期3 DRT前瞻性、多中心Ⅱ期临床研究——不同病理类型生存再分析(PPRA‐RTOG003)[J]. 中华放射肿瘤学杂志,2016,25(10): 1051‐1056.DOI: 10.3760/cma.j.issn.1004‐4221.2016.10.006.
Deng R, Li T, Li JC, et al.A prospective, multicenter, phase Ⅱ clinical study of three‐dimensional radiotherapy concurrent chemothery for stage Ⅳ non‐small‐cell lung cancer‐the impact of different pathological types on survival(PPRA‐RTOG003)[J]. Chin J Radiat Oncol, 2016,25(10): 1051‐1056.DOI: 10.3760/cma.j.issn.1004‐4221.2016.10.006.

[1]	国家癌症中心/国家肿瘤质控中心. CT模拟机质量控制指南[J]. 中华放射肿瘤学杂志, 2022, 31(8): 677-684.